The latest biotech news

novartis spinal muscular atrophy gene therapy

News and Trends 19 May 2020

Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU

Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […]

May 19, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 18 May 2020

Update: Spanish Food Startup Raises €12M to Grow Healthier Animal Fats

Update (18/05/2020): Cubiq Foods has received a €5M investment from food technology investor Blue Horizon Ventures. With the funds, the startup aims to accelerate the production of its omega 3 fat additives based on cell culture, expecting to launch two products by the end of the year. 31/01/2019 Based in Barcelona, Cubiq Foods is developing […]

May 18, 2020 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 May 2020

Affibody Signs €208M Deal To Market Autoimmune Drug in China

Swedish biotech Affibody and Chinese firm Inmagene Biopharmaceuticals will work together to develop and commercialize Affibody’s phase II-stage drug for autoimmune diseases such as psoriasis. Under the agreement, Inmagene will commercialize Affibody’s treatment in the Greater China region and South Korea, as well as develop the drug in the Asia Pacific region excluding Japan. Meanwhile, […]

May 15, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 15 May 2020

Synthetic Biology Could Lead to Clean Energy Using Light and Carbon Dioxide

Researchers in Germany and France have combined synthetic biology with microfluidics to create artificial photosynthetic droplets, which could lead to the production of organic chemicals and clean fuels that is more efficient than nature can achieve alone. In a study recently published in Science, the research team developed an automated way to produce artificial versions […]

May 15, 2020 - 3 minutesmins - By David Kirk

News and Trends 15 May 2020

Update: ADC Therapeutics’ IPO Hits Above Target with €215M

Update (15/05/2020): The Swiss biotech ADC Therapeutics has priced its IPO on the New York Stock Exchange far above the initial target of €172M, raising a total of €215.2M ($232.7M). ADC Therapeutics ended up offering more than 12 million shares at a price of €17.57 ($19) per share, which was higher than the €16.65 ($18) […]

May 15, 2020 - 4 minutesmins - By Laura Cowen

genmab janssen blood cancer multiple myeloma

News and Trends 14 May 2020

Oncopeptides’ Share Issue Bags €133M to Take Cancer Drug to Market

Swedish biotech Oncopeptides has raised €133M (SEK 1.4B) by issuing new company shares, surpassing expectations and driving the launch of its targeted chemotherapy drug in the US. In what could be one of European biotech’s largest equity boosts this year, the company exceeded initial plans to raise €111M (SEK 1.2M) through Nasdaq Stockholm following a […]

May 14, 2020 - 3 minutesmins - By Anita Chakraverty

Innovative Medicines Initiative Covid 19

News and Trends 14 May 2020

EU Initiative Pumps up Funding for Covid-19 Research to €117M

The funding will go towards eight research projects that have been selected out of 144 proposals received by the EU’s Innovative Medicines Initiative. In March, the Innovative Medicines Initiative (IMI) opened a fast-track call for proposals on diagnostics and treatments for the coronavirus outbreak. Due to the large number of high-quality proposals received, the IMI […]

May 14, 2020 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 May 2020

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […]

May 13, 2020 - 4 minutesmins - By Helen Albert

News and Trends 12 May 2020

Gamida Cell’s Bone Marrow Transplant Cuts Treatment Time in Phase III

A rapid-acting bone marrow transplant developed by the Israeli biotech Gamida Cell was engrafted in blood cancer patients 10 days faster than standard umbilical cord blood transplants in a phase III trial. The trial recruited 125 blood cancer patients in more than 50 clinical centers globally. One group received a standard transplant of donor umbilical […]

May 12, 2020 - 2 minutesmins - By Jonathan Smith

pharma mediolanum farmaceutici menarini elsalys stemline

News and Trends 11 May 2020

Italian Pharma Getting Back to Normal With Two Biotech Acquisitions

Despite the country being hard hit with Covid-19, Italian pharma seems to be getting back to business as usual with two oncology-related biotech acquisitions in the last week. The most recent acquisition was of French immuno-oncology company ElsaLys Biotech by Mediolanum Farmaceutici, a pharmaceutical group based in Milan. The French biotech has several candidate drugs […]

May 11, 2020 - 4 minutesmins - By Helen Albert

News and Trends 8 May 2020

Phase III Failure Sinks Drug for Rare Neurological Disorder

The Italian biotech Newron is halting the development of the experimental drug sarizotan after it failed to meet efficacy endpoints in phase III, dashing hopes for an approved drug for Rett syndrome. Expectations had been high that the oral drug might be able to treat breathing difficulties associated with the rare genetic disorder after promising […]

May 8, 2020 - 4 minutesmins - By Anita Chakraverty

genomics machine learning personalized medicine

News and Trends 8 May 2020

€7M Series A To Democratize Genomics with AI-Driven Cloud Software

The UK-based bioinformatics firm Lifebit Biotech has closed a €7M Series A funding round, which will help the startup to accelerate the global market expansion of its AI-driven, cloud-based genomics analysis software. The round was led by the Parisian VC firm Idinvest Partners and also included returning investors Pentech Ventures, Beacon Capital, and Connect Ventures. […]

May 8, 2020 - 3 minutesmins - By Laura Cowen

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU

Update: Spanish Food Startup Raises €12M to Grow Healthier Animal Fats

Affibody Signs €208M Deal To Market Autoimmune Drug in China

Synthetic Biology Could Lead to Clean Energy Using Light and Carbon Dioxide

Update: ADC Therapeutics’ IPO Hits Above Target with €215M

Oncopeptides’ Share Issue Bags €133M to Take Cancer Drug to Market

EU Initiative Pumps up Funding for Covid-19 Research to €117M

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Gamida Cell’s Bone Marrow Transplant Cuts Treatment Time in Phase III

Italian Pharma Getting Back to Normal With Two Biotech Acquisitions

Phase III Failure Sinks Drug for Rare Neurological Disorder

€7M Series A To Democratize Genomics with AI-Driven Cloud Software

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!